Endothelial Activation by aPL: A Potential Pathogenetic Mechanism for the Clinical Manifestations of the Syndrome
- 30 September 2000
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 15 (2), 237-240
- https://doi.org/10.1006/jaut.2000.0412
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesNew England Journal of Medicine, 1999
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.JCI Insight, 1998
- β2-Glycoprotein I as a ‘Cofactor’ for anti-phospholipid reactivity with endothelial cellsLupus, 1998
- EditorialLupus, 1997
- Immunology of the antiphospholipid antibody syndromeArthritis & Rheumatism, 1996
- HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Role of β2-glycoprotein I in the antiphospholipid antibody binding to endothelial cellsLupus, 1995
- HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway productsAtherosclerosis, 1991
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988